Afamelanotide

Afamelanotide is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone, used to prevent phototoxicity in erythropoietic protoporphyria patients. It increases melanin production, providing photoprotection. Afamelanotide is a first-in-class, synthetic, 13-amino acid peptide analogue of the endogenous alpha melanocyte-stimulating hormone (α-MSH). It differs structurally from its endogenous counterpart by only two amino acids – these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer biological half-life. Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014 and subsequent FDA approval in October 2019. Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008. It is grouped under the following drug class(es): Peptides. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include afamelanotidum, Melanotan and Scenesse (TN). Its PubChem CID is 16197727.

CAS No 75921-69-6
Molecular Formula C78H111N21O19
Molecular Weight 1646.8 g/mol
Synonyms (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Zoho Contact Form

"*" indicates required fields

I am a*
This field is for validation purposes and should be left unchanged.

Frequently Asked Questions